Preferential hyperacuity perimeter as a functional tool for monitoring exudative age-related macular degeneration in patients treated by intravitreal ranibizumab

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 9, 2011, Pages 7012-7018

  Querques, Giuseppe ^a   Querques, Lea ^a,b   Rafaeli, Omer ^c   Canoui Poitrine, Florence ^a,d   Bandello, Francesco ^b   Souied, Eric H ^a  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c Notal Vision Ltd   (Israel)

^d HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MALE; PERIMETER; PREFERENTIAL HYPERACUITY PERIMETER; PRIORITY JOURNAL; RETINA ANGIOGRAPHY; RETINA MACULA AGE RELATED DEGENERATION; SENSITIVITY AND SPECIFICITY; SLIT LAMP; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; TREATMENT OUTCOME; VISUAL ACUITY; DRUG MONITORING; EXUDATE; FOLLOW UP; INSTRUMENTATION; INTRAVITREAL DRUG ADMINISTRATION; OPTICAL COHERENCE TOMOGRAPHY; PERIMETRY; PHYSIOLOGY; PROSPECTIVE STUDY; REPRODUCIBILITY; RETINA MACULA DEGENERATION; RETREATMENT; VISUAL DISORDER; VISUAL FIELD;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DRUG MONITORING; EXUDATES AND TRANSUDATES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; RETREATMENT; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, OPTICAL COHERENCE; VISION DISORDERS; VISUAL ACUITY; VISUAL FIELD TESTS; VISUAL FIELDS;

EID: 80054875835     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-7517     Document Type: Article

References (30)

1. Bressler NM. Age-related macular degeneration is the leading cause of blindness. J Am Med Assoc. 2004;291:1900-1901.
2. Chen Y, Wiesmann C, Fuh G, et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol. 1999;293:865-881.
3. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355: 1419-1431.
4. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab vs verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.
5. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566-583.
6. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148:43-58.
7. Querques G, Azrya S, Martinelli D, et al. Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting. Br J Ophthalmol. 2010;94:292-296.
8. Rothenbuehler SP, Waeber D, Brinkmann CK, et al. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Am J Ophthalmol. 2009;147:831-837.
9. Cohen SY, Dubois L, Tadayoni R, et al. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol. 2009;148:409-413.
10. Olsen TW, Feng X, Kasper TJ, Rath PP, Steuer ER. Fluorescein angiographic lesion type frequency in neovascular age-related macular degeneration. Ophthalmology. 2004;111:250-255.
11. Complications of Age-related Macular Degeneration Prevention Trial (CAPT) Research Group. Risk factors for choroidal neovascularization and geographic atrophy in the complications of agerelated macular degeneration prevention trial. Ophthalmology. 2008;115:1474-1479.
12. Bedell HE, Tong J, Woo SY, House JR, Nguyen T. Orientation discrimination with macular changes associated with early AMD. Optom Vis Sci. 2009;86:485-491.
13. Neelam K, Nolan J, Chakravarthy U, Beatty S. Psychophysical function in age-related maculopathy. Surv Ophthalmol. 2009;54: 167-210.
14. Loewenstein A. The significance of early detection of age-related macular degeneration: Richard and Hinda Rosenthal Foundation Lecture, The Macula Society 29th Annual Meeting. Retina. 2007; 27:873-878.
15. Alster Y, Bressler NM, Bressler SB, et al. Preferential Hyperacuity Perimeter (PreView PHP) for detecting choroidal neovascularization study. Ophthalmology. 2005;112:1758-1765.
16. Goldstein M, Loewenstein A, Barak A, et al. Results of a multicenter clinical trial to evaluate the preferential hyperacuity perimeter for detection of age-related macular degeneration. Retina. 2005;25: 296-303.
17. Trevino R. Recent progress in macular function self assessment. Ophthalmic Physiol Optics. 2008;28:183-192.
18. Das R, Shi Y, Silvestri G, et al. Distortion maps from preferential hyperacuity perimetry are helpful in monitoring functional response to Lucentis therapy. Retina. 2009;29:1013-1018.
19. Loewenstein A, Ferencz J, Lang Y, et al. Toward earlier detection of choroidal neovascularization secondary to age-related macular degeneration: multicenter evaluation of a preferential hyperacuity perimeter designed as a home device. Retina. 2010;30:1058-1064.
20. Querques G, Berboucha E, Leveziel N, Pece A, Souied EH. Preferential hyperacuity perimeter in assessing responsiveness to ranibizumab therapy for exudative age-related macular degeneration. Br J Ophthalmol. 2011;95:986-991.
21. Bland JM, Altman DG. Statistics notes: calculating correlation coefficients with repeated observations: Part 1. Correlation within subjects (Abstract). BMJ. 1995;310:446.
22. Doris N, Hart PM, McCleland J, et al. Relation between macular morphology and visual function in patients with choroidal neovascularisation of age-related macular degeneration. Br J Ophthalmol. 2001;85:184-188.
23. Hogg R, Stevenson MR, Winder J, et al. Macular lesion composition and location influence visual function in AMD. Br J Ophthalmol. 2003;87:609-614.
24. Querques G, Bux AV, Prato R, et al. Correlation of visual function impairment and optical coherence tomography findings in patients with adult-onset foveomacular vitelliform macular dystrophy. Am J Ophthalmol. 2008;146:135-142.
25. Fletcher DC, Schuchard RA. Visual function in patients with choroidal neovascularization resulting from age-related macular degeneration: the importance of looking beyond visual acuity. Optom Vis Sci. 2006;83:178-189.
26. Bedell HE, Tong J, Woo SY, House JR, Nguyen T. Orientation discrimination with macular changes associated with early AMD. Optom Vis Sci. 2009;86:485-491.
27. Liu L, White J. Early age-related macular degeneration impairs tolerance to stimulus degradation. Optom Vis Sci. 2010;87:532-542.
28. Wang YZ, Wilson E, Locke KG, Edwards AO. Shape discrimination in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2002;43:2055-2062.
29. Arimura E, Matsumoto C, Nomoto H, et al. Correlations between M-CHARTS and PHP findings and subjective perception of metamorphopsia in patients with macular diseases. Invest Ophthalmol Vis Sci. 2011;52:128-135.
30. Loewenstein A, Malach R, Goldstein M, et al. Replacing the Amsler grid: a new method for monitoring patients with age-related macular degeneration. Ophthalmology. 2003;110:966-970.